Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer: United Kingdom National Cancer Research Institute trial AB01

Ruth E Langley; James Carmichael; Alison L Jones; David A Cameron; Wendi Qian; Barbara Uscinska; Anthony Howell; Mahesh Parmar

doi:10.1200/JCO.2005.01.1817

Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer: United Kingdom National Cancer Research Institute trial AB01

Ruth E Langley, James Carmichael, Alison L Jones, David A Cameron, Wendi Qian, Barbara Uscinska, Anthony Howell, Mahesh Parmar

Research output: Contribution to journal › Article › peer-review

Abstract

To compare the effectiveness and tolerability of epirubicin and paclitaxel (EP) with epirubicin and cyclophosphamide (EC) as first-line chemotherapy for metastatic breast cancer (MBC).

Original language	English
Pages (from-to)	8322-30
Number of pages	9
Journal	Journal of Clinical Oncology
Volume	23
Issue number	33
DOIs	https://doi.org/10.1200/JCO.2005.01.1817
Publication status	Published - 20 Nov 2005

Keywords / Materials (for Non-textual outputs)

Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
Breast Neoplasms
Cyclophosphamide
Disease-Free Survival
Epirubicin
Female
Great Britain
Humans
Middle Aged
Neoplasm Metastasis
Paclitaxel
Statistics, Nonparametric
Survival Analysis

Access to Document

10.1200/JCO.2005.01.1817

Fingerprint

Dive into the research topics of 'Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer: United Kingdom National Cancer Research Institute trial AB01'. Together they form a unique fingerprint.

Cite this

Langley, R. E., Carmichael, J., Jones, A. L., Cameron, D. A., Qian, W., Uscinska, B., Howell, A., & Parmar, M. (2005). Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer: United Kingdom National Cancer Research Institute trial AB01. Journal of Clinical Oncology, 23(33), 8322-30. https://doi.org/10.1200/JCO.2005.01.1817

@article{036f2d0b4f3d4ba484a75d4f6c64a12d,

title = "Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer: United Kingdom National Cancer Research Institute trial AB01",

abstract = "To compare the effectiveness and tolerability of epirubicin and paclitaxel (EP) with epirubicin and cyclophosphamide (EC) as first-line chemotherapy for metastatic breast cancer (MBC).",

keywords = "Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Cyclophosphamide, Disease-Free Survival, Epirubicin, Female, Great Britain, Humans, Middle Aged, Neoplasm Metastasis, Paclitaxel, Statistics, Nonparametric, Survival Analysis",

author = "Langley, {Ruth E} and James Carmichael and Jones, {Alison L} and Cameron, {David A} and Wendi Qian and Barbara Uscinska and Anthony Howell and Mahesh Parmar",

year = "2005",

month = nov,

day = "20",

doi = "10.1200/JCO.2005.01.1817",

language = "English",

volume = "23",

pages = "8322--30",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "33",

}

Langley, RE, Carmichael, J, Jones, AL, Cameron, DA, Qian, W, Uscinska, B, Howell, A & Parmar, M 2005, 'Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer: United Kingdom National Cancer Research Institute trial AB01', Journal of Clinical Oncology, vol. 23, no. 33, pp. 8322-30. https://doi.org/10.1200/JCO.2005.01.1817

Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer: United Kingdom National Cancer Research Institute trial AB01. / Langley, Ruth E; Carmichael, James; Jones, Alison L et al.
In: Journal of Clinical Oncology, Vol. 23, No. 33, 20.11.2005, p. 8322-30.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer

T2 - United Kingdom National Cancer Research Institute trial AB01

AU - Langley, Ruth E

AU - Carmichael, James

AU - Jones, Alison L

AU - Cameron, David A

AU - Qian, Wendi

AU - Uscinska, Barbara

AU - Howell, Anthony

AU - Parmar, Mahesh

PY - 2005/11/20

Y1 - 2005/11/20

N2 - To compare the effectiveness and tolerability of epirubicin and paclitaxel (EP) with epirubicin and cyclophosphamide (EC) as first-line chemotherapy for metastatic breast cancer (MBC).

AB - To compare the effectiveness and tolerability of epirubicin and paclitaxel (EP) with epirubicin and cyclophosphamide (EC) as first-line chemotherapy for metastatic breast cancer (MBC).

KW - Adult

KW - Aged

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Breast Neoplasms

KW - Cyclophosphamide

KW - Disease-Free Survival

KW - Epirubicin

KW - Female

KW - Great Britain

KW - Humans

KW - Middle Aged

KW - Neoplasm Metastasis

KW - Paclitaxel

KW - Statistics, Nonparametric

KW - Survival Analysis

U2 - 10.1200/JCO.2005.01.1817

DO - 10.1200/JCO.2005.01.1817

M3 - Article

C2 - 16293863

SN - 0732-183X

VL - 23

SP - 8322

EP - 8330

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 33

ER -

Langley RE, Carmichael J, Jones AL, Cameron DA, Qian W, Uscinska B et al. Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer: United Kingdom National Cancer Research Institute trial AB01. Journal of Clinical Oncology. 2005 Nov 20;23(33):8322-30. doi: 10.1200/JCO.2005.01.1817